Emerging retatrutide, a combined-action treatment targeting both GLP-1 and GIP receptors, is sparking considerable interest within the healthcare community. Preliminary clinical studies have revealed significant losses in overall weight and gains in physiological markers for people with overweight. Experts believe this ground-breaking approach m… Read More